FDA Modernization Act 2.0 Paves the Way to Computational Biology and Clinical Trials in a Dish
- PMID: 37486997
- PMCID: PMC10902210
- DOI: 10.1161/CIRCULATIONAHA.123.065585
FDA Modernization Act 2.0 Paves the Way to Computational Biology and Clinical Trials in a Dish
Keywords: animal use alternative; artificial intelligence; clinical trials as topic; drug development; drug discovery; induced pluripotent stem cells.
Conflict of interest statement
Figures
References
-
- Wax PM. Elixirs, diluents, and the passage of the 1938 federal food, drug and cosmetic act. Ann Intern Med. 1995; 122:456–461. - PubMed
-
- Mullard A. 2022 FDA approvals. Nat Rev Drug Discov. 2023; 22:83–88. - PubMed
-
- Cho S, Discher DE, Leong KW, Vunjak-Novakovic G, Wu JC. Challenges and opportunities for the next generation of cardiovascular tissue engineering. Nat Methods. 2022; 19:1064–1071. - PubMed
-
- Zhang A, Xing L, Zou J, Wu JC. Shifting machine learning for healthcare from development to deployment and from models to data. Nat Biomed Eng. 2022; 6:1330–1345. - PubMed
-
- Sayed N, Liu C, Ameen M, Himmati F, Zhang JZ, Khanamiri S, Moonen JR, Wnorowski A, Cheng L, Rhee JW, Gaddam S, Wang KC, Sallam K, Boyd JH, Woo YJ, Rabinovitch M, Wu JC. Clinical trial in a dish using iPSCs shows lovastatin improves endothelial dysfunction and cellular cross-talk in LMNA cardiomyopathy. Sci Transl Med. 2020; 12:eaax9276. - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
